01—Abstract
Summary
Summary of the 8-K filed July 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Elevance Health (ELV) filed an 8-K on July 28, 2025 to disclose a board change: the Board elected Steven H.
Collis as an independent director effective August 1, 2025, with a term expiring at the 2027 annual meeting. He was also appointed to the Audit and Finance Committees, and the Board determined he qualifies as an "audit committee financial expert." The filing states he has no material related-party interest under Item 404(a) and no arrangement with any other person tied to his election. For investors, this is a governance event rather than a financial one.
The filing contains no earnings, guidance, capital allocation, or operational results. The company's press release frames the appointment as part of a structured board refresh intended to add healthcare operations and long-term value-creation experience, with Chair Ramey Peru citing alignment with strategic objectives. The most relevant point for shareholders is the addition of a director with substantial healthcare supply-chain leadership and audit-committee financial expertise, which may strengthen oversight of financial reporting.
Director compensation follows the company's standard non-employee director program, as described in a previously filed 10-Q exhibit. The filing does not indicate any change in company strategy or financial condition.
02—Key points
Key Highlights
- Steven H. Collis elected as an independent director effective August 1, 2025, with a term expiring at the 2027 annual meeting
- Collis appointed to both the Audit Committee and the Finance Committee
- Board determined Collis qualifies as an 'audit committee financial expert' under SEC rules
- Collis is Executive Chairman of Cencora (formerly AmerisourceBergen), previously serving 13 years as President and CEO (2011-2024)
- No related-party transactions or arrangements disclosed in connection with his election
- Compensation follows the standard non-employee director program filed as Exhibit 10.7 to the Q2 2025 10-Q
- Press release characterizes the appointment as part of an ongoing board refresh, not a response to a specific event
03—Questions
Frequently Asked Questions
Who is the new board member and what is his background?
Steven H. Collis is Executive Chairman of the Board of Cencora (formerly AmerisourceBergen). He joined Cencora in 1994, became President and CEO in 2011, and moved to Executive Chairman in 2024. He led the company through strategic transformation and global expansion across the pharmaceutical and healthcare supply chain.
Does this appointment change Elevance's financial outlook or guidance?
No. The 8-K contains no financial results, guidance, or forecasts. It is limited to a board election and committee appointments.
Why does his appointment to the Audit Committee matter to investors?
The Board determined Collis qualifies as an audit committee financial expert. Such expertise can strengthen oversight of financial reporting, internal controls, and audit processes, which shareholders generally view favorably.
Does Collis have any conflicts of interest or special arrangements?
The filing states there is no arrangement or understanding between Collis and any other person regarding his election, and that he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
How will Collis be compensated as a director?
He will receive compensation under the company's standard non-employee director program, which is described in Exhibit 10.7 to the company's Form 10-Q for the quarter ended June 30, 2025. The 8-K does not specify individual compensation amounts.
04—Continue